Key Highlights

  • Third-quarter 2026 Revenue was USD 2.8 million, against USD 0.5 million a year earlier.
  • RNK Health revenue was USD 2.0 million, and app subscription revenue was USD 0.9 million.
  • Net loss was USD 977 thousand, or USD 0.08 per common share.
  • Cash balance was USD 1.9 million, with USD 11.4 million in short-term investments.

Gaxos.ai (NASDAQ:GXAI) reported revenue of USD 2,814,527 for the third quarter ended September 30, 2026, against an estimate of USD 3.00 million and USD 498,271 in the third quarter of 2025. Net loss attributable to common shareholders was USD 0.08 per share, against an estimate of a loss of USD 0.11 and USD 0.14 a year earlier. The company operates artificial intelligence applications and health optimization services. Its common stock trades on the Nasdaq Stock Market, and the company reports results for subscription software and health services.

Quarterly Financial Results

The company said it generated revenue primarily through RNK Health, which provides non-clinical services to support patient care, of USD 1,958,620. It also generated USD 855,907 from subscription services from its Art-Gen.ai, unGPT.ai and Bible.ai applications. In the third quarter of 2025, revenue was USD 498,271.

Loss from operations was USD 1,114,422, against USD 1,314,755, a decrease of USD 200,333, or 15.2%. Net loss was USD 977,004, against USD 1,140,873, a decrease of 14.4%. Net loss attributable to common shareholders was USD 929,639, or USD 0.08 per basic and diluted share, against USD 1,001,474, or USD 0.14 per share.

Nine-Month Results

For the nine months ended September 30, 2026, total revenues were USD 7,081,251, against USD 692,974 in the same period of 2025. Loss from operations was USD 5,526,299, against USD 3,689,144, an increase of 49.8%. Net loss was USD 3,473,483, against USD 3,197,507, an increase of 8.6%.

In connection with the sale of its gaming assets, the company recorded a gain on sale of Assets of USD 1,749,890 for the nine months, which includes the value of the buyer's common shares received of USD 1,760,000. As of September 30, 2026, it owned 2,450,000 common shares of Game Foundry with a cost basis of USD 1,960,000.

Liquidity and Financing

As of September 30, 2026, the company had a cash balance of USD 1,895,334, short-term investments of USD 11,402,526 and Working Capital of USD 12,693,960. It used net cash in operations of USD 4,538,025 during the nine months.

On August 17, 2026, in connection with an August 14, 2026 inducement letter, the holder of existing warrants exercised them for cash at a reduced exercise price of USD 1.20 per share. This resulted in gross proceeds of approximately USD 3,609,185, with net proceeds of USD 3,174,307 after Placement agent fees and other offering expenses of USD 434,878. The company also has a sales agreement with H.C. Wainwright and Co. to offer and sell up to USD 5,600,000 of common stock under its effective shelf registration statement.

The filing states that operating losses are projected to continue, primarily due to corporate overhead, research and development, and the costs of being a public company. It also notes that RNK Health was formed on September 23, 2024 as a subsidiary, and entered into an operating agreement with Nekwellness, LLC on October 10, 2024 to engage in Marketing certain products.